Leukocare Overview

  • Founded
  • 2003
Founded
  • Status
  • Private
  • Employees
  • 1,000
Employees
  • Latest Deal Type
  • PE Growth
  • Financing Rounds
  • 7

Leukocare General Information

Description

Developer of protein stabilizing technologies intended for a reduction in systemic inflammation in patients during cardiac surgery. The company offers formulation technologies through the application of bioinformatics and artificial intelligence for biopharmaceuticals, viral vectors and vaccines as well as biofunctionalized devices, thereby reducing leukocyte activity in an extracorporeal blood circuit employing an antibody.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Other Industries
Other Devices and Supplies
Other Pharmaceuticals and Biotechnology
Primary Office
  • Building 6, First Floor
  • Am Klopferspitz 19
  • 82152 Munich
  • Germany
+49 089 000000000

Leukocare Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Leukocare Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Leukocare‘s full profile, request access.

Request a free trial

Leukocare Patents

Leukocare Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3036965-A1 A novel method for stabilization of a biopharmaceutical drug product during processing Pending 16-Sep-2016 000000000000
JP-2019537552-A A novel method for stabilizing biopharmaceutical products during processing Pending 16-Sep-2016 000000000000
US-20190216925-A1 A novel method for stabilization of a biopharmaceutical drug product during processing Pending 16-Sep-2016 000000000000
AU-2017328632-A1 A novel method for stabilization of a biopharmaceutical drug product during processing Pending 16-Sep-2016 000000000000
US-20190216734-A1 A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation Pending 16-Sep-2016 A61K9/08

Leukocare Executive Team (6)

Name Title Board Seat Contact Info
Michael Scholl Chief Executive Officer & Co-Founder
Georg Dönges Ph.D Chief Financial Officer
Andreas Seidl Chief Operating Officer
Gerhard Ries Ph.D Member of Supervisory Board
You’re viewing 4 of 6 executive team members. Get the full list »

Leukocare Board Members (7)

Name Representing Role Since
0000000 0000000 00.0 Self Supervisory Board Member 000 0000
000000 000000 00.0 Leukocare Chairman of the Supervisory Board 000 0000
0000-0000 0000000 00.0 Self Supervisory Board Member 000 0000
0000 000000 Self Board Member 000 0000
00000000 0000000000 Leukocare Supervisory Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Leukocare Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Leukocare Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Leukocare‘s full profile, request access.

Request a free trial